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ABSTRACT The objective of this study was to evaluate
the possible association of drug treatments in pregnant women
with a higher risk of congenital abnormalities of the external
ear, particularly microtia/anotia, in their children. The fre-
quency of drug treatments was compared in the mothers of
cases with isolated or multiple (syndromic) ear abnormalities
and in the mothers of three different controls: controls matched
to cases, all controls (these controls had no defects) and mal-
formed controls in the population-based large dataset of the
Hungarian Case-Control Surveillance of Congenital Abnor-
malities. There was no significantly higher use of any drug in
the mothers of 354 cases with isolated external ear abnormali-
ties than in the mothers of different controls. However, of 156
cases with multiple ear abnormalities, 11 had mothers with
hydroxyethylrutosidea treatment and a characteristic pattern
of congenital abnormalities was found in these children. Four
cases with multiple ear abnormalities were born to epileptic
mothers treated with valproate, phenytoin and polytherapy in
two cases. Drug treatments are not important in the origin of
isolated ear abnormalities. However, a higher risk of multiple
ear abnormalities was found in children born to mothers with
treatment of hydroxyethylrutosidea or antiepileptic drugs
during pregnancy.
Key Words: drug treatment, ear abnormality, hydroxye-
thylrutosidea, population-based case-control study, pregnancy
INTRODUCTION
The aim of this PhD project is to estimate the possible causal
association of structural birth defects (i.e. congenital abnormalities
[CAs]) of external ears, mainly microtia and anotia in the offspring
of mothers with teratogenic factors during pregnancy because the
etiology of these visible CAs is less-known (Aase and Tegtmeier
1979; Mastroiacovo et al. 1995; Suutarla et al. 2007). The minor
proportion of ear CAs can be explained by major mutant genes
(Mastroiacovo et al. 1995; Llano-Rivas et al. 1999), but among
environmental factors only high altitude (Castilla et al. 1999) had
some association with higher risk of microtia and anotia. Prenatal
drug exposures were also mentioned as potential causal factors in
the origin of microtia/anotia without specification of any drug
(Castilla and Orioli 1986).
Thus the objective of the present study was to evaluate different
drugs separately in pregnant women who had offspring with exter-
nal ear CAs in a population-based case-control study based on the
large dataset of the Hungarian Case-Control Surveillance of Con-
genital Abnormalities (HCCSCA) (Czeizel et al. 2001a). The birth
outcomes of children with external ear CAs has been reported in
another paper (Paput et al. 2010).
MATERIALS AND METHODS
The objective of the HCCSCA is to compare the pharmaceutical
and other environmental exposures in pregnant mothers of cases
and controls.
Cases and controls
Cases with CA were selected from the Hungarian Congenital
Abnormality Registry (HCAR) (Czeizel 1997) for the HCCSCA.
The reports of cases with CA is mandatory for physicians from the
birth of a child until its first birthday to the HCAR and most CAs are
reported by obstetricians (in Hungary practically all deliveries take
place in inpatient obstetric clinics and birth attendants are obstetri-
cians) or pediatricians (working at neonatal units of inpatient
obstetric clinics as well as of various general and special surgical,
cardiologic, orthopedic, and oto-rhino-laryngologic inpatient and
outpatient pediatric clinics). Autopsy was obligatory for all infant
deaths and was usually (about 80%) in stillborn fetuses during the
study period. Pathologists sent a copy of the autopsy report to the
HCAR if defects were identified in stillborn fetuses or infant deaths.
Fetal defects diagnosed by prenatal diagnostic centers with or
without elective termination of pregnancy have also been reported
to the HCAR since 1984.
Minor anomalies or morphological variants without serious
medical or cosmetic consequences are recorded in the HCAR, but
these cases are excluded from the estimation of different CA rates.
CAs were differentiated into two main categories: isolated CAs
(only one organ is affected) and multiple CAs (concurrence of two
or more CAs in the same person affecting at least two different
organ systems) (Czeizel et al. 1988). If minor anomalies were com-
ponents of multiple CAs, they were considered at the evaluation of
multimalformed cases.
The total (birth + fetal) prevalence of cases with CA diagnosed
from the second trimester of pregnancy through the age of 1 year
was 35 per 1000 informative offspring (liveborn infants, stillborn
fetuses and electively terminated malformed fetuses) in the HCAR,
1980–1996 (Czeizel 1997), and about 90% of major CAs were
recorded in the HCAR during the 17 years of the study period
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(Czeizel et al. 1993). The proportion of liveborn infants, stillborn
fetuses and electively terminated malformed fetuses was 97.1%,
1.1% and 1.8%, respectively.
The diagnosis of ear CAs was checked in the HCAR and modi-
fied if necessary by two steps: (i) If cases with unspecified ear CAs
were reported to the HCAR, an extra effort was made by the
assistant of the HCAR to contact the medical doctors who reported
these cases to specify the diagnosis; and (ii) Parents of cases asked
coworkers of the HCAR to organize parental meetings, and there
were two parental meetings for the families of cases with ear CAs
in the institute of the HCAR in 1988 and 1996. These meetings had
three aims: (i) provide information for parents regarding ear CAs
and respond to their questions; (ii) experience exchange among
parents; and (iii) provide examination of these cases by experts.
Thus we were able to examine personally about one-third of cases
with isolated ear CAs.
Both isolated CAs (single, complex, sequence) and multiple CAs
(MCAs) (MCA-syndrome, MCA-association and random combi-
nation) are further differentiated into three subcategories (Puho
et al. 2008). The abbreviation of IECA is used for the category
isolated ear CAs. However, at the evaluation of IECA cases, the
so-called complex CAs are worth mentioning because severe
microtia and anotia (i.e. CAs of the auricle[s]), were frequently
associated with narrowing or absence of the external auditory canal/
meatus and sometimes with the CAs of middle ear; thus, there are
two or three CAs in the same organ. Most MCAs are not recognized
and/or identified as MCA-syndromes or MCA-associations; there-
fore, it is not possible to differentiate unrecognized/unidentified
MCAs from random combinations of component CAs within the
category of MCAs. This diagnostic problem explains that we use
the term unclassified multiple CAs in general (Puho et al. 2008).
Multiple ear CAs had anotia/microtia; therefore, the abbreviation of
unclassified multiple anotia/microtia is UMAM. These cases were
described in a previous paper in detail (Paput et al. 2011).
However, cases with IECA and UMAM in the study were
selected from the dataset of the HCCSCA.
There were three exclusion criteria in the selection of cases with
CA from the HCAR for the HCCSCA: (i) cases reported after three
months of birth or elective termination of pregnancy to the HCAR
(23% of the total, including mainly mild CAs); (ii) cases with three
mild CAs as congenital dysplasia of the hip based on Ortolani click,
congenital inguinal hernia, major hemangioma; and (iii) cases with
CA-syndromes caused by major gene mutations or chromosomal
aberrations (with preconception origin). Thus cases with identified
MCA-syndromes, including ear CAs, were excluded from the study.
Controls were identified in the National Birth Registry of the
Central Statistical Office for the HCCSCA. These controls were
defined as newborn infants without defect and in general two con-
trols were matched to every case according to sex, birth week in the
year when cases were born and district of parents’ residence.
However, these controls were used in two different approaches: (i)
matched controls of cases with IECA or UMAM; and (ii) all con-
trols because their large number improves the statistical power.
However, there was a third control group: (iii) malformed controls
selected from the HCAR, that is, liveborn cases with isolated CA
(but without cases with IECA) or cases with unclassified MCAs
(but without UMAM).
Exposure and confounder data collection
Medically recorded prospective data
Mothers of cases and controls were asked in a mailed explanatory
letter to send us the prenatal maternity logbook and other medical
records (mainly discharge summaries of their deliveries) regarding
their diseases and related treatments during pregnancy and their
child’s CA. Prenatal care was mandatory for pregnant women in
Hungary (if a mother did not visit prenatal care, she received no
maternity grant and leave), thus nearly 100% of pregnant women
visited prenatal care, on average seven times. The first visit was
between sixth and twefth gestational weeks. The task of obstetri-
cians was to record all pregnancy complications, maternal diseases
and related drug prescriptions in the prenatal maternity logbook.
Retrospective self-reported maternal information
A structured questionnaire together with a list of diseases and drugs,
and a printed informed consent form were also mailed to the
mothers immediately after the selection of cases and controls. To
standardize the answers, mothers were asked to read the enclosed
list of diseases and medications as a memory aid before replying.
Mothers were also asked to provide a signature for informed
consent which authorized us to record the name and address of their
children in the HCCSCA.
The period between birth or elective termination of pregnancy
and return of the information package (questionnaire, logbook, and
informed consent) in our prepaid envelope was 3.5 1.2 and
5.2 2.9 months for cases and controls, respectively.
Supplementary data collection
Regional nurses were asked to visit all non-respondent mothers of
cases (including malformed controls) at home, to help mothers fill
in the questionnaire, evaluate available medical documents, and
obtain data regarding lifestyle (smoking, drinking, and illicit drug
use) and some important symptoms (e.g. high fever) in diseases
during pregnancy through a personal interview of mothers and their
close relatives living with them. The lifestyle data were collected
only in these subsamples due to the unreliability of retrospective
maternal information (Czeizel et al. 2004a). Regional nurses visited
only 200 non-respondent and 600 respondent control mothers as
part of the two validation studies (Czeizel et al. 2003; Czeizel
and Vargha 2004), as the ethics committee considered that this
follow-up would be disturbing to the parents of healthy children.
Regional nurses used the same method in these control mothers as
in non-respondent case and malformed control mothers.
Drug treatment was evaluated according to three different aspects
(Czeizel 2009a): (1) The source of information: (a) data only from
the prenatal maternity logbooks and/or other medical records; (b)
data only from the questionnaire; and (c) concordant data from both
medical records and the questionnaire. (2) The timing of exposures
(i.e. drug treatments). The gestational age was calculated from the
first day of the last menstrual period. Three time intervals were
considered: (i) The first month of gestation because it is before
organogenesis. The first two weeks are before conception while the
third and fourth weeks comprise the preimplantation and implanta-
tion periods of zygotes and blastocysts, including omnipotent stem
cells. Thus CAs cannot be induced by short-term environmental
agents in the first month of gestation and explains the ‘all-or-
nothing effect’ (i.e. total loss or normal further development). (ii)
The second and third months of gestation. The auricle is formed
from the first and second branchial arches by a series of auricular
hillocks that surround the first pharyngeal groove during the sixth
postconceptional week (Poswillo 1973), thus the critical period of
external ear CAs is in the eighth gestational week. Thus, mainly the
second gestational month as the most sensitive time window of the
potential exposures was evaluated, but because of the inaccuracy of
this time calculation (both in the gestational age and exposure
time), the third gestational month was also considered (Czeizel
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2008). (iii) The fourth through ninth months of gestation (i.e. preg-
nancy after the organ-forming period). (3) Drug treatments were
evaluated according to the chemical structure of medicinal prod-
ucts, route of administration, doses, and duration of treatment.
Among potential confounding factors, maternal age, birth order,
and marital and employment status as indicator of socioeconomic
status because it correlated well with the level of education and
income (Puho et al. 2005), and the use of pregnancy supplements,
mainly folic acid (Czeizel 2009b) were considered.
Finally, necessary data were collected for 96.3% of cases (84.4%
from reply, 11.9% from visit) and for 83.0% of controls (81.3%
from reply, 1.7% from visit). Informed consent was signed and
returned by 98.4% of mothers.
The procedure of data collection was changed in 1997 because
regional nurses visit and question all cases and controls, but the
recent data had not been validated at the time of this analysis, thus
only the dataset of 17 years between 1980 and 1996 is evaluated
here.
Classification and evaluation of cases with ear CA
At the evaluation of cases with CAs of the external and middle ear,
different classifications were suggested (Marx 1926; Meurman
1957; Tasse et al. 2005); the following classification was used in the
HCCSCA:
Type I microtia, as a minor anomaly. The external ear is small
and the auricle retains most of its normal structure; therefore, all
anatomical structures are distinguishable. The external auditory
meatus is present. Each case with type I microtia was excluded from
the study of IECA as minor anomaly but type I microtia as compo-
nent anomaly was evaluated in UMAM cases.
Type II microtia, as a mild CA. The structure of the smaller
external ear is moderately anomalous. The auricle can be hook-, S-
or question mark-shaped in appearance with a more or less irregular
mass of cartilage, but the external auditory meatus is usually
present.
Type III microtia, as a severe CA. The external ear is rudimentary
with abnormal structure: the auricle does not include cartilage, only
soft tissues and there is no external auditory meatus.
Anotia, as a severe CA. All external ear structures are absent, thus
there is no external auditory meatus/canal. The skin of the cheek
passes smoothly over the aural area without definite elevation or
depression.
Complex ear CA, as a severe CA. These cases had middle ear
CAs and anotia/microtia with narrowing or absence of the external
auditory canal/meatus.
The diagnosis of ear CAs was checked in the HCCSCA and
modified if necessary also by two steps: (i) Results of recent
medical examinations helped to achieve more accurate diagnoses;
and (ii) Frequent personal examination was conducted in selected
cases with complex ear CA and with familial origin in our institute
or visited at home by the principal investigator of the study.
Statistical analysis
The software package SAS version 8.02 (SAS Institute, Cary, NC,
USA) was used. First, frequency tables were made for the main
maternal variables to describe the study groups. Second, the char-
acteristics of pregnant women with IECA or UMAM and controls
were compared using Student’s t-test for quantitative and c2 statis-
tics or odds ratios (OR) with 95% confidence interval (CI) for
categorical variables. Third, the frequency of drug treatments used
during pregnancy was compared between the groups of cases with
IECA or UMAM and different control groups. At the comparison of
cases with their matched controls, conditional logistic regression
model was used, while at the comparison of cases and all controls
or malformed controls, the ordinary logistic regression model was
used. At the calculation of adjusted OR with 95% CI age, employ-
ment status, birth order, and diseases of mothers were considered.
RESULTS
IECAs were diagnosed in liveborn infants. Of 354 cases with IECA,
74 and 236 had mild and severe microtia, respectively (Table 1).
Mild microtia did not associate with the atresia of the external
auditory canal, but was associated with preauricular tag/pit/sinus in
nine cases (12.2%). Severe microtia was associated with preauricu-
lar tag/pit/sinus in 69 cases (29.2%), and 212 cases (89.8%) had
also aural stenosis or atresia. Anotia occurred only 24 cases (6.8%),
and all of these cases had aural stenosis or atresia, while eight (33.3)
were affected with preauricular tag/pit/sinus as well. There is an
obvious correlation between the severity of microtia/anotia and the
frequency of above associated CAs. The fourth group included 20
cases with ‘other’ IECA, and of these 20 cases, 18 were personally
examined. Five cases had middle ear CAs (atresia of auditory canal
with fusion of ear ossicles in four cases, atresia of the auditory canal
without membranous labyrinth in the middle ear and organ Corti in
one case) and anotia/microtia; 12 cases were affected with aural
atresia/stenosis and anotia in one side with microtia in the other
side, and one case was affected with polyotia and microtia. Two
cases had only medically recorded diagnosis of ear CAs without
personal examination (inner ear CA with anotia in one case, and
absence of Eustachian tube with microtia in another case). Thus, of
354 cases with IECA, each had microtia or anotia with or without
other ear CAs.
Table 1 Distribution of cases with different groups/types of IECA and UMAM, in addition to their sex ratio and side distribution of ear CAs
IECA groups
Total Sex ratio (male)
Side
Right Left Together Bilateral Unknown
No. No. % No. % No. % No. % No. % No.
Mild microtia 74 40 54.1 39 60.9 23 35.9 62 96.9 2 3.1 10
Severe microtia 236 125 53.0 138 61.1 82 36.3 220 97.3 6 2.7 10
Anotia 24 12 50.0 12 50.0 10 41.7 22 91.7 2 8.3 0
Other 20 14 70.0 4 21.1 3 15.8 7 36.8 12 63.2 1
Total 354 191 54.0 193 57.9 118 35.4 311 93.4 22 6.6 21
UMAM 156 102 65.4 47 56.0 37 44.0 84 62.2 52 38.2 20
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Of 156 cases with UMAM in the HCCSCA, four (2.6%) occurred
in stillborn fetuses, and of 152 liveborn cases, 28 (18.4%) died
during the infant period. Two, three, four to five and six to nine
component CAs were recorded in 36 (23.1%), 41 (26.3%), 51
(32.7%) and 28 (32.7%) UMAM cases, respectively.
The sex ratio (i.e. the proportion of males) of IECA cases shows
a slight male preponderance (Table 1), but the male excess was
strong in the group of ‘other’ ear CAs. UMAM cases showed a
more robust male predominance.
Laterality may also have some association with the origin of ear
CAs. Microtia/anotia had an obvious predominance of unilateral
manifestation, with some excess of the right side in cases with
microtia (Table 1). However, this trend does not exist in the ‘other’
group, because nearly two-thirds of these cases had bilateral mani-
festation of ear CAs. The less frequent occurrence of unilateral ear
CA is characteristic for UMAM cases as well.
The maternal characteristics in the groups of cases with IECA
and different controls are shown in Table 2. The number of controls
was 38 151 and represented 1.8% of all Hungarian newborns. The
mean maternal age in the case group of IECA did not differ signifi-
cantly from control mothers. The mean birth order was higher in the
mothers of IECA cases compared to the mothers of matched con-
trols and all controls; however, there was no difference in the mean
birth order of the mothers of IECA cases and malformed controls.
The rate of unmarried women was lower in the mothers of matched
controls. The distribution of employment status was different
between case mothers and matched or all control mothers, but not
between cases and malformed control mothers. These differences
reflect the lower proportion of the two groups of high socioeco-
nomic status (i.e. professional and managerial employment in the
mothers of IECA cases and malformed controls). The lowest pro-
portion of professional women was found in the group of IECA
cases. Of 354 case mothers, 190 (53.7%) used folic acid, while this
rate was similar in matched (59.1%) and all (54.5%) control
mothers but lower in the mothers of malformed controls (49.5%).
Of 354 mothers of IECA cases, 112 had personal information
regarding smoking and drinking habits during pregnancy, 20
(17.8%) were smokers while two (1.8%) were regular drinkers
(more than one drink per week). The proportion of smokers was
19.1% in the group of all controls and 21.2% in the mothers of
malformed controls.
The maternal characteristics of 156 cases with UMAM were
also evaluated (Table 3). There was no significant difference in the
mean maternal age or birth order among the study groups. Marital
status also did not show any significant difference. However, the
distribution of employment status in the mothers of UMAM cases
differed from control groups due to mainly the lowest proportion
of managerial and skilled workers and the highest proportion of
semiskilled workers and ‘other’ (mainly due to students). The use
of folic acid was similar in the mothers of cases (53.8%), matched
(53.8%) and all (54.5%) controls, but lower in the mothers of
malformed controls (46.0%).
Table 4 summarizes the data of pregnancy complications in the
mothers of IECA cases because some drug treatments might be
connected with these pathological conditions. There was no asso-
ciation of any pregnancy complication with higher risk of IECA.
Pregnancy complications in the mothers of UMAM cases are not
shown here because the associated component CAs may have a
stronger effect for these variables than ear CAs.
The number and incidence of acute maternal diseases were the
following in the mothers of 354 cases with IECA: influenza/
common cold with secondary complications (75, 21.2%); and acute
diseases of the respiratory system (43, 12.1%), digestive system
(2, 0.6%), urinary tract (32, 9.0%), genital organs (19, 5.4%) and
others (14, 4.0%). Only high fever related to influenza/common
cold showed association with higher risk of IECA (adjusted OR
with 95% CI. 4.3, 1.9–7.4). The number and prevalence of chronic
diseases, such as diabetes mellitus (3, 0.8%) and epilepsy (3, 0.8%)
was low, essential hypertension (20, 5.6%), hemorrhoids (14,
4.0%), primary hypotension (13, 3.7%), varicose veins in the lower
extremities (9, 2.5%) and migraine (6, 1.7%) occurred more fre-
quently. However, there was no higher risk of IECA in cases born to
mothers with these chronic diseases.
Two acute diseases occurred more frequently in the mothers of
UMAM cases than in the mothers of controls. Six UMAM cases had
severe skin scar and unilateral microtia born to mothers with vari-
cella (chickenpox) during pregnancy. High fever related to influenza/
common cold with secondary complications and tonsillitis together
occurred more frequently in the mothers of UMAM cases (16.7%)
than in the mothers of matched controls (4.3%), all controls (6.0%)
and malformed controls (11.1%). Maternal chronic diseases were
also evaluated without any association with higher risk of UMAM.
The objective of the present study was the evaluation of different
drugs in the origin of IECA or UMAM.
The frequency of drug treatments (used at least by five mothers of
IECA cases) during the pregnancy in the group of cases and controls
is shown in Table 5. There was no permanent higher risk of IECA
in cases compared to all control groups; higher risk of some drugs
was found only in separate comparisons. Allylestrenol was used
more frequently by the mothers of IECA cases than by the mothers
of matched controls. The occurrence of nitrofurantoin treatment
was more common in the mothers of IECA cases than in mothers of
all controls. However, two drugs, prednisolone or tribenoside were
used more frequently by the mothers of IECA cases than by the
mothers of all controls and malformed controls. These risk figures
were 4.1 and 3.1 in prednisolone compared to all controls and
malformed controls, while 2.6 in tribenoside compared both to all
controls and malformed controls, thus we cannot neglect them.
In the next step the above drugs were evaluated therefore only in
the second and/or third gestational month (i.e. in the critical period
of IECA if at least three mothers of IECA cases who used them)
(Table 5). There was no pregnant woman with prednisolone treat-
ment in the second or third gestational month. The onset of pred-
nisolone treatment was in the fifth, sixth, seventh and ninth months
in two, two, one and one woman, respectively. Of seven pregnant
women with tribenoside use, only one was treated with this drug in
the critical period of IECA (i.e. from the first month to the ninth
month), while the onset of tribenoside treatment was in the fourth,
sixth and seventh month in one, three and two women, respectively.
Thus the causal association of these drug treatments with higher
risk of IECA can be excluded. However, allylestrenol was used
more frequently in the second and/or third gestational month by the
mothers of IECA cases than by the mothers of matched controls.
In addition, the use of aminophenazone + carbromal (Demalgon,
Chinoin, Budapest, Hungary) was also more frequent during the
second and/or third gestational month in the mothers of IECA cases
than in the mothers of all controls. However, these higher risks were
not seen in the comparison of IECA cases and other controls; in
addition, these significant associations disappeared if only medi-
cally recorded allylestrenol or aminophenazone + carbromal treat-
ments were evaluated.
The frequency of drug treatments (used by at least three case
mothers) during pregnancy in women who had cases with UMAM
is shown in Table 6. Aminophylline was used more frequently by
the mothers of UMAM cases than by the mothers of matched
controls. At the comparison of cases with UMAM and all controls,
Drugs in the origin of microtia/anotia 129
© 2011 The Authors
Congenital Anomalies © 2011 Japanese Teratology Society
Ta
bl
e
2
A
ge
,b
irt
h
o
rd
er
,
an
d
so
ci
oe
co
no
m
ic
st
at
us
o
fm
o
th
er
s
in
th
e
st
ud
y
gr
ou
ps
D
em
og
ra
ph
ic
fa
ct
or
s
Ca
se
sw
ith
IE
CA
(n
=
35
4)
M
at
ch
ed
co
n
tr
ol
s
(n
=
51
1)
A
ll
co
n
tr
ol
s
(n
=
38
15
1)
M
al
fo
rm
ed
co
n
tr
ol
s
(n
=
21
14
0)
M
at
er
na
la
ge
No
.
%
No
.
%
c2
2
=
P
=
No
.
%
c2
2
=
P
=
No
.
%
c2
2
=
P
=
19
o
r
le
ss
37
10
.4
50
9.
8
32
77
8.
6
23
11
10
.9
20
–2
9
25
8
72
.9
38
6
75
.5
0.
8
0.
66
27
60
2
72
.3
2.
5
0.
29
14
44
5
68
.3
3.
9
0.
14
30
o
r
m
o
re
59
16
.7
75
14
.7
72
72
19
.1
43
84
20
.7
t=
P
=
t=
P
=
t=
P
=
M
ea
n

SD
25
.2

5.
2
24
.9

4.
6
0.
9
0.
37
25
.5

4.
9
1.
1
0.
25
25
.5

5.
3
1.
1
0.
29
Bi
rt
h
o
rd
er
1
15
2
42
.9
26
6
52
.1
c2
1
=
7.
0
18
20
9
47
.7
c2
1
=
3.
2
99
10
46
.9
c2
1
=
2.
2
2
o
r
m
o
re
20
2
57
.1
24
5
47
.9
P
=
0.
00
8
19
94
2
52
.3
P
=
0.
07
11
23
0
53
.1
P
=
0.
14
t=
P
=
t=
P
=
t=
P
=
M
ea
n

SD
1.
9

1.
0
1.
7

0.
9
3.
1
0.
00
2
1.
7

0.
9
4.
2
<
0.
00
01
1.
9

1.
1
0.
0
1.
00
So
ci
oe
co
no
m
ic
st
at
us
O
R
w
ith
95
%
CI
O
R
w
ith
95
%
CI
O
R
w
ith
95
%
CI
U
nm
ar
rie
d
20
5.
6
11
2.
2
2.
9,
1.
2–
6.
6
14
71
3.
9
1.
3,
0.
8–
2.
1
11
79
5.
6
1.
1,
0.
7–
1.
7
Em
pl
oy
m
en
t
Pr
of
es
sio
na
l
20
5.
6
56
11
.0
43
53
11
.4
17
82
8.
4
M
an
ag
er
ia
l
76
21
.5
13
6
26
.6
10
13
4
26
.6
45
93
21
.7
Sk
ill
ed
w
o
rk
er
10
0
28
.2
14
9
29
.2
c2
6
=
24
.9
11
69
0
30
.6
c2
6
=
54
.2
58
80
27
.8
c2
6
=
10
.0
Se
m
isk
ill
ed
w
o
rk
er
65
18
.4
80
15
.7
P
<
0.
00
01
57
83
15
.2
P
<
0.
00
01
3.
56
4
16
.9
P
<
0.
00
01
U
ns
ki
lle
d
w
o
rk
er
22
6.
2
21
4.
1
18
59
4.
9
13
94
6.
6
H
ou
se
w
ife
45
12
.7
28
5.
5
20
38
5.
3
19
44
9.
2
O
th
er
26
7.
3
41
8.
0
22
94
6.
0
19
83
9.
4
130 L. Paput et al.
© 2011 The Authors
Congenital Anomalies © 2011 Japanese Teratology Society
Ta
bl
e
3
M
at
er
na
lc
ha
ra
ct
er
ist
ic
s
o
fc
as
es
w
ith
U
M
A
M
an
d
o
ft
he
ir
co
n
tr
ol
s
M
at
er
na
lv
ar
ia
bl
es
Ca
se
sw
ith
U
M
A
M
(n
=
15
6)
M
at
ch
ed
co
n
tr
ol
s
(n
=
27
7)
A
ll
co
n
tr
ol
s
(n
=
38
15
1)
M
al
fo
rm
ed
co
n
tr
ol
s
(n
=
11
93
)
Qu
an
tita
tiv
e
N
o.
%
N
o.
%
Co
m
pa
ris
on
N
o.
%
Co
m
pa
ris
on
N
o.
%
Co
m
pa
ris
on
M
at
er
na
la
ge
(ye
ars
)
19
o
r
le
ss
17
10
.9
24
8.
7
32
77
8.
6
14
1
11
.8
20
–2
9
10
5
67
.3
19
5
70
.4
c2
2(2
)=
0.
7
P
=
0.
71
27
60
2
72
.3
c2
2
=
2.
1
P
=
0.
35
78
5
65
.8
c2
2
=
0.
2
P
=
0.
92
30
o
r
m
o
re
34
21
.8
58
20
.9
72
72
19
.1
26
7
22
.4
M
ea
n

SD
25
.6
5.
2
25
.8
5.
3
T
=
0.
4,
P
=
0.
70
25
.5
4.
9
t=
0.
3,
P
=
0.
80
25
.5
5.
5
T
=
0.
2,
P
=
0.
83
B
irt
h
o
rd
er
c2
1
=
0.
1
c2
1
=
0.
1
c2
1
=
0.
1
1
77
49
.4
13
2
47
.7
P
=
0.
73
18
20
9
47
.7
P
=
0.
68
56
9
47
.7
P
=
0.
70
2
o
r
m
o
re
79
50
.6
14
5
52
.3
19
94
2
52
.3
62
4
52
.3
M
ea
n

SD
1.
8
1.
1
1.
8
1.
1
T
=
0.
0,
P
=
1.
00
1.
7
0.
9
t=
1.
4,
P
=
0.
17
1.
9
1.
2
T
=
1.
0,
P
=
0.
32
So
ci
oe
co
no
m
ic
st
at
us
N
o.
%
N
o.
%
O
R,
95
%
CI
N
o.
%
O
R,
95
%
CI
N
o.
%
O
R,
95
%
CI
U
nm
ar
rie
d
12
7.
7
21
7.
6
0.
8,
0.
4–
1.
8
14
71
3.
9
1.
8,
0.
9–
3.
2
60
5.
0
1.
6,
0.
8–
3.
1
Em
pl
oy
m
en
ts
ta
tu
s
Pr
of
es
sio
na
l
17
10
.9
35
12
.6
43
53
11
.4
82
6.
9
M
an
ag
er
ia
l
31
19
.9
73
26
.4
10
13
4
26
.6
26
8
22
.5
Sk
ill
ed
w
o
rk
er
37
23
.7
80
28
.9
c2
6
=
16
.4
11
69
0
30
.6
c2
6
=
32
.6
31
2
26
.2
c2
6
=
15
.2
Se
m
isk
ill
ed
w
o
rk
er
30
19
.2
40
14
.4
P
=
0.
03
57
83
15
.2
P
<
0.
00
01
21
0
17
.6
P
=
0.
02
U
ns
ki
lle
d
w
o
rk
er
8
5.
1
16
5.
8
18
59
4.
9
79
6.
6
H
ou
se
w
ife
8
5.
1
15
5.
4
20
38
5.
3
13
1
11
.0
O
th
er
25
16
.0
18
6.
5
22
94
6.
0
11
1
9.
3
Drugs in the origin of microtia/anotia 131
© 2011 The Authors
Congenital Anomalies © 2011 Japanese Teratology Society
only one medicinal product: combination of aminophenazone +
carbromal (Demalgon) was associated with a higher risk of
UMAM. The use of paracetamol was more frequent in the mothers
of four UMAM cases than in the mothers of all controls and mal-
formed controls. The occurrence of penamecillin in the mothers of
cases was associated with a higher risk of UMAM at the compari-
son with matched and all controls. However, there was only one
drug: hydroxyethylrutosidea, which had a significantly higher use
by the mothers of UMAM cases than by the mothers of all the three
groups of control mothers.
In the next step drugs were evaluated only in the second and/or
third gestational month if at least four mothers of UMAM cases
used (Table 6). Bromhexine and penamecillin were associated with
a higher risk of UMAM at the comparison of case mothers and all
control mothers. Dipyrone was associated with a higher risk of
UMAM at the comparison of case mothers with matched control
and all control mothers. Paracetamol was used only by three
mothers of UMAM cases during the second and/or third gestational
month, but its occurrence was higher in the mothers of UMAM
cases than in the mothers of all control and malformed control
mothers. However, when only medically recorded drug treatments
were evaluated, these associations disappeared. However, two
drugs, aminophenazone + carbromal in five mothers and hydroxy-
ethylrutosidea in seven mothers of UMAM cases were used during
the critical period of UMAM more frequently than by the mothers
of all the three control groups. Of five case mothers with
aminophenazone + carbromal treatment, three were medically
recorded in the prenatal maternity logbook, and if only medically
recorded drug treatments were considered, the pervious association
was diminished to the borderline level. However, of seven case
mothers with hydroxyethylrutosidea treatment, six were medically
recorded, thus the very high OR did not change. These cases are
shown in Table 7 because the pattern of component CAs of these
UMAM cases is characteristic: beyond anotia/microtia or complex
ear CA, poly/syndactyly, genital organ CAs (hypospadias, pseudo-
hermaphroditism, vaginal atresia, undescended testis) and anal
atresia showed a higher observed number/occurrence than their
expected number on the basis of the data set of the HCCSCA. Thus
the combination of these component CAs is not random and it
indicates a specific MCA-syndrome.
The well-known human teratogenic drugs were also evaluated
independently on the number of mothers of UMAM cases. Of four
multimalformed cases born to epileptic mothers, two had two com-
ponent CAs (anotia + hypospadias after valproate monotherapy
and severe microtia + nail hypoplasia after phenytoin mono-
therapy), one case had five component CAs (severe microtia +
coloboma + patent ductus arteriosus + choanal atresia + syndactyly
in feet: this case can be diagnosed as CHARGE-association and it
was associated with the use of phenytoin, primidone, diazepam
and mephenytoin) and one had six component CAs (severe
microtia + stenosis of pulmonary artery + rectal stenosis + giant
kidney + clubfoot + absence of vertebra after the maternal
Table 4 Incidence of pregnancy complications in the mothers of IECA cases, matched controls, all controls and malformed controls
Pregnancy complications
Cases with IECA
(n = 354)
Matched controls
(n = 511)
All controls
(n = 38 151)
Malformed controls
(n = 21 140)
No. % No. % OR† 95%CI No. % OR† 95%CI No. % OR† 95%CI
Threatened abortion 51 14.4 94 18.4 0.8 0.6–1.2 6510 17.1 0.8 0.6–1.1 3193 15.1 1.0 0.7–1.3
Nausea/vomiting, severe 28 7.9 54 10.6 0.7 0.5–1.5 3856 10.1 0.8 0.7–1.0 1614 7.6 1.0 0.8–1.2
Preeclampsia 10 2.8 15 2.9 1.0 0.4–2.3 1156 3.0 1.0 0.5–1.8 621 2.9 1.0 0.5–1.8
Pregnancy related renal
disease
6 1.7 11 2.2 0.8 0.3–2.1 492 1.3 1.3 0.6–3.0 312 1.5 1.1 0.5–2.5
Edema/excessive weight
gain without
hypertension
2 0.6 14 2.7 0.2 0.0–1.0 912 2.4 0.2 0.1–0.9 405 1.9 0.3 0.1–1.1
Gestational diabetes 1 0.3 3 0.6 0.6 0.1–6.0 229 0.6 0.5 0.1–3.6 113 0.5 0.6 0.1–4.2
Placental disorders,
including placenta
previa, premature
separation of placenta,
antepartum hemorrhage
1 0.3 7 1.4 0.3 0.0–2.6 593 1.6 0.2 0.0–1.4 275 1.3 0.2 0.0–1.6
Polyhydramnios 1 0.3 2 0.4 0.7 0.1–8.1 191 0.5 0.6 0.1–4.0 155 0.7 0.4 0.1–2.7
Threatened preterm
delivery, including
cervical incompetence
43 12.1 75 14.7 0.9 0.6–1.3 5447 14.3 0.8 0.6–1.2 2417 11.4 1.1 0.8–1.5
Anemia 51 14.4 104 20.4 0.6 0.4–0.9 6358 16.7 0.8 0.6–1.1 2998 14.2 1.0 0.7–1.3
Other (e.g. trauma,
poisoning, blood
isoimmunization)
11 3.1 21 4.1 0.8 0.4–1.7 1770 4.6 0.7 0.4–1.2 824 3.9 0.8 0.4–1.5
†OR adjusted for maternal age and employment status, in addition to birth order and maternal diseases.
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treatment of primidone, phenobarbital and phenacemide). Thus the
mothers of the latter two cases had polytherapy of antiepileptic
drugs. Other human teratogenic drugs did not associate with a
higher risk of UMAM, one case born to a mother with oxytetracy-
cline is shown in Table 7.
DISCUSSION
The objective of the study was to reveal the possible association of
drug treatments during pregnancy with higher risk of ear CAs.
Cases with IECA did not show any association with drug treatments
thus medicinal products are not important in the origin of IECA.
However, the group of antiepileptics and hydroxyethylrutosidea
were associated with a higher risk of UMAM.
The association of antiepileptics with the higher risk of CAs is
well known. Our data showed that the spectrum of CAs caused by
antiepileptic drugs includes UMAM as well. The possible associa-
tion of hydroxyethylrutosidea with higher risk of UMAM was sup-
ported by five findings: (i) this drug treatment in the mothers of
most cases overlapped with the critical period of UMAM; (ii) most
hydroxyethylrutosidea were medically recorded in the prenatal
maternity logbook, thus recall bias cannot distort this association;
(iii) the indication/reason of hydroxyethylrutosidea (i.e. varicose
veins of lower extremities), does not associate with a higher risk
of CAs, including MCAs (Bánhidy et al. 2010a); (iv) other drugs
cannot explain this association; and last, but not least, (v) compo-
nent CAs of these UMAM cases showed a characteristic pattern of
a specified MCA-syndrome, including external ear CAs, and poly/
syndactyly and CAs of caudal region (i.e. genital organs and anal
atresia).
Rutosidea, a flavonoid derivate drug was discovered as a twin
vitamin of vitamin C by the Nobel-laureate Albert Szent-Györgyi
and his coworker, Steve Rusznyák in 1936 (Rusznyák and Szent-
Györgyi 1936). Rutosidea had beneficial effect for capillary dis-
eases; therefore, it was marketed in Hungary. Later, a derivative of
rutosidea, O–(beta-hydroxyethyl)-rutosidea, (i.e. oxerutin), was
produced in some countries because hydroxyethylrutosidea can
inhibit the aggregation of red blood cells and protect the endothe-
lial cells of vessels (Negwar and Scharnow 2007). Hydroxyethyl-
rutosidea was used frequently for the treatment of capillary
fragility, thrombophlebitis, and varicositas. After oral treatment of
hydroxyethylrutosidea, its maximum plasma concentration is
achieved within 1–9 h with a half-life of total elimination between
10 and 25 h.
In Hungary, hydroxyethylrutosidea is produced as Venoruton
(Biogal, Debrecen, Hungary) in tablets for oral treatment of 300 mg
and 500 mg. The recommended oral treatment is three 300-mg or
two 500-mg tablets per day for 3–5 weeks. Hydroxyethylrutosidea
is also frequently used in pregnant women, but its possible terato-
genic effect was not mentioned in the well-known handbooks (Hei-
nonen et al. 1977; Shepard and Lemire 2004; Briggs et al. 2005).
Vogt et al. (2005) reported a possible association of hydroxyethyl-
rutosidea treatment in pregnant women with a higher risk of ocular
coloboma in their children. Animal experiments did not show clini-
cally important concentration of hydroxyethylrutosidea in fetuses
(Borvendég 2000), nevertheless hydroxyethylrutosidea was not rec-
ommended during pregnancy before the fourth gestational month
(Borvendég 2000). Contrary to this recommendation, hydroxyeth-
ylrutosidea is among the most frequently used drugs in Hungarian
pregnant women. Most pregnant women followed the recom-
mended doses of hydroxyethylrutosidea treatment (i.e. daily 900–
1000 mg), but in general it was much longer than the recommended
3–5 weeks; the mean duration of treatments was about four months.
Most mothers with hydroxyethylrutosidea use were treated by
other drugs as well, but the teratogenic potential of these drugs,
such as clotrimazole (Czeizel et al. 1999a), metronidazole (Czeizel
and Rockenbauer 1988), ampicillin (Czeizel et al. 2001b), sulpha-
methoxydiazine (Czeizel et al. 2004b), parenteral penicillins
(Czeizel et al. 1999b), oxytetracycline (Czeizel and Rockenbauer
2000), nitrofurantoin (Czeizel et al. 2001c), paracetamol (Rebor-
doso et al. 2008), dipyrone (Bánhidy et al. 2006), promethazine
(Bártfai et al. 2008), Reparon (EGIS, Budapest, Hungary; Bánhidy
et al. 2010b) and Kefalgin (EGIS, Budapest, Hungary; Ács et al.
2006) were tested in the HCCSCA. Only ampicillin showed weak
association with the higher risk of cleft palate and oxytetracycline
with higher risk of some CAs, including cardiovascular CAs and
MCAs.
Of course, a large number of statistical tests may result in a
significant difference (P < 0.05) in every 20th calculation due to
chance (Shaffer 1995).
Our results raised a possible association between the use of a
medicinal product (aminophenazone + carbromal) in pregnant
women and higher risk of UMAM in their children; thus, further
studies are required.
The strength of our material is the population-based dataset of the
HCAR and HCCSCA in an ethnically homogeneous Hungarian
(Caucasian) population. The diagnosis of ear CA was based on the
report of medical doctors and checked in the HCAR and later
modified, if necessary, on the basis of recent medical examinations
in the HCCSCA and frequently completed by the personal exami-
nation of cases by a specialist. Finally, the majority of maternal
diseases and related drug treatments were prospectively and medi-
cally recorded in the prenatal maternity logbooks. In addition, the
use of matched and malformed controls diminished the recall bias
in maternal self-reported information (Rockenbauer et al. 2001;
Czeizel 2009a) and the effect of confounders.
However, this dataset also has limitations (e.g. most multimal-
formed cases were not examined personally, thus the diagnosis of
component CAs was based on the reports of medical doctors).
In conclusion, there was a higher risk of UMAM in the children of
epileptic mothers with the treatment of antiepileptics and a MCA-
syndrome was delineated in UMAM cases of mothers with hydroxy-
ethylrutosidea treatment. Thus, the use of hydroxyethylrutosidea is
contraindicated in the second and third months of pregnancy.
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